bearish

Biopharma Week in Review - October 7, 2024

68 Views08 Oct 2024 07:36
Issuer-paid
Last week, HIMS and unapproved GLP-1 sellers (LFMD) were put on notice by the FDA. KZR’s study was stopped and placed on clinical hold, but the stock rose.
What is covered in the Full Insight:
  • Biopharma News Overview
  • Regulatory Updates
  • Clinical Data Highlights
  • Market Reactions
  • Sector Shifts and Strategy Changes
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 9-minute read)
Discussions
(Paid Plans Only)
chart-bar
Logo
Water Tower Research
Research from Water Tower Research
Water Tower Research
Equity Bottom-UpThematic (Sector/Industry)
  • Biopharma Week in Review - October 7, 2024
    08 Oct 2024
x